Tech Company Financing Transactions
Cajal Neuroscience Funding Round
On 11/29/2022, Cajal Neuroscience secured $96 million in Series A funding from Lux Capital, The Column Group and Alexandria Venture Investments.
Transaction Overview
Company Name
Announced On
11/29/2022
Transaction Type
Venture Equity
Amount
$96,000,000
Round
Series A
Investors
Proceeds Purpose
The company intends to use the funds to expand its development efforts.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
1616 Eastlake Ave. E 300
Seattle, WA 98102
USA
Seattle, WA 98102
USA
Phone
Undisclosed
Website
Email Address
Overview
Cajal Neuroscience is a drug discovery company focused on neurodegenerative disease. Cajal is building a research and development team with the passion, drive, and scientific expertise to execute its bold mission of generating novel disease-altering therapies for neurodegeneration.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Ignacio Munoz-Sanjuan
Chief Operating Officer
Andrew Dervan
Chief Scientific Officer
Ian Peikon
Vice President
Julie Harris
Browse more venture capital transactions:
Prev: 11/29/2022: EcoSync venture capital transaction
Next: 11/29/2022: Upollo venture capital transaction
Share this article
About Our VC Transactions Data
We do our best to report on every notable VC transaction. All VC database entries reported here are sourced from a variety of public sources. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs